Skip to content

Our
Science

Bifunctional Antibodies

Antibodies are proteins made by immune system cells as part of the body’s immune response, and thus are a key target for drug development in a range of diseases. Typically, these molecules target just a single type of cell. However, recent research has suggested that if antibodies could target more than one cell at a time, the efficacy and specificity of the antibody-based therapy would increase. For example, combining an antibody that targets a tumor cell with an antibody that targets a cell that destroys tumor cells creates a bifunctional antibody that can target both—bringing together all the right immune system players to get the job done.

RC28: Our bifunctional antibody
RC28 is RemeGen’s bifunctional antibody investigational candidate for several ophthalmic (eye) diseases; RC28 is being studied in clinical studies for wet age-related macular degeneration (wAMD), diabetic retinopathy, and diabetic macular edema—all diseases in which blood vessels leak fluid into the eye, causing progressive vision loss and blindness.

Specifically, RemeGen’s candidate is made from an antibody that targets vascular endothelial growth factor (VEGF) and an antibody that targets fibroblast growth factor (FGF) These two growth factors are key pathway regulators in the formation of new blood vessels (angiogenesis), and are found in higher levels in patients with diabetes.

The resulting molecule, RC28, is able to target and inhibit both growth factors. By targeting two different points in the angiogenesis pathway, RC28 increases the likelihood of inhibition and ultimately slows disease progression.
RC18
Antibody and Fusion Protein R&D Platform
By taking the best pieces of different proteins to create new fusion antibodies, we can better target the immune system in autoimmune diseases.
More about antibody and fusion protein
RC48
Antibody-Drug Conjugate (ADC) Platform
These molecular trios specifically deliver chemotherapies directly to tumor cells—all while sparing healthy cells.
More about ADCs